**Pharmacological Agents Targeting Thrombo-inflammation in COVID-19:**

**Review and Implications for Future Research**

**Short title:** Therapeutic Targets for COVID-19-associated Thrombosis

Behnood Bikdeli, MD, MS1,2,3\*, Mahesh V. Madhavan, MD1,3\*, Aakriti Gupta MD MS1,2,3, David Jimenez MD, PhD4, John R. Burton, MD1, Caroline Der Nigoghossian, PharmD1, Taylor Chuich, PharmD1, Shayan Nabavi Nouri, MD1, Isaac Dreyfus, MD1, Elissa Driggin, MD1, Sanjum Sethi MD MPH1, Kartik Sehgal MD5,6, Saurav Chatterjee MD7, Walter Ageno, MD8, Mohammad Madjid, MD, MS9, Yutao Guo, MD, PhD10,45, Liang V. Tang, MD11, Yu Hu, MD11, Laurent Bertoletti MD PhD12, Jay Giri, MD, MPH13,14,15, Mary Cushman, MD, MSc16, Isabelle Quéré, MD, PhD17, Evangelos P. Dimakakos, MD18, C. Michael Gibson, MD5,6, Giuseppe Lippi, MD19, Emmanuel J. Favaloro, PhD20,21, Jawed Fareed, PhD22, Alfonso J. Tafur, MD, MS23,24, Dominic P. Francese, MPH3, Jaya Batra, MD1, Anna Falanga, MD25, Kevin J. Clerkin MD MS1, Nir Uriel MD MSc1, Ajay Kirtane MD SM1,3, Claire McLintock, MD26, Beverley J. Hunt, MD27, Alex C. Spyropoulos, MD28, Geoffrey D. Barnes, MD, MSc29,30, John W. Eikelboom, MBBS31, Ido Weinberg, MD5,32, Sam Schulman, MD, PhD33,34,35, Marc Carrier, MD, MSc36, Gregory Piazza, MD, MS5,37, Joshua A. Beckman, MD38, Martin B. Leon MD1,3, Gregg W. Stone, MD3,39, Stephan Rosenkranz, MD40, Samuel Z. Goldhaber, MD5, 37, Sahil A. Parikh, MD1,3, Manuel Monreal, MD, PhD41, Harlan M. Krumholz, MD, SM2,42,43, Stavros V. Konstantinides, MD, PhD44, Jeffrey I. Weitz, MD34,35, Gregory Y.H. Lip, MD45,46 **The** **Global COVID-19 Thrombosis Collaborative Group**

From 1NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; 2Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut; 3Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; 4Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (IRYCIS), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; 5Harvard Medical School, Boston, Massachusetts; 6Beth Israel Deaconess Medical Center, Boston, Massachusetts 7 North Shore and Long Island Jewish University Hospitals 8Department of Medicine and Surgery, University of Insubria, Varese, Italy; 9McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas; 10Department of Cardiology, Chinese PLA General Hospital, Beijing, China; 11 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;12 Department of “Médecine Vasculaire et Thérapeutique”, CIC 1408, INNOVTE, CHU de St-Etienne and INSERM UMR1059, Université Jean-Monnet, F-42055, Saint-Etienne, France; 13Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia; 14Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia; 15Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; 16The University of Vermont Larner College of Medicine, Burlington, Vermont; 17Department of Vascular Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN network, Montpellier, France; 18Oncology Unit GPP, Sotiria General Hospital Athens School of Medicine, Athens, Greece; ; 19Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy; 20Laboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia; 21Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia; 22Loyola University Medical Center, Chicago, Illinois; 23Pritzker School of Medicine at the University of Chicago, Chicago, Illinois; 24Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois;25University of Milan Bicocca, Monza, Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, 26Auckland City Hospital, Auckland, New Zealand, 27St Thomas’ Hospital, London, United Kingdom, 28The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York 29 Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan 30Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan; 31Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; 32Massachusetts General Hospital, Boston, Massachusetts; 33Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 34McMaster University, Hamilton, Ontario, Canada; 35Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada;36The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; 37Brigham and Women’s Hospital, Boston, Massachusetts; 38Vanderbilt University School of Medicine, Nashville, Tennessee; 39The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; 40Department of Cardiology, Heart Center at the University of Cologne, and Cologne Cardiovascular Research Center (CCRC), University of Cologne, Germany; 41Department of Internal Medicine, Hospital Universitari Germans Trials I Pujol, Universidad Católica de Murcia, Barcelona, Spain; 42Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut; 43Section of Cardiovascular Medicine, Department of Internal Medicie, Yale School of Medicine, New Haven, Connecticut; 44Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany; 45Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; 46Aalborg University, Aalborg, Denmark

\*Drs. Bikdeli and Madhavan contributed equally to this manuscript.

**Word Count** (not including abstract, references and tables): 5,396 words

**Corresponding Authors:**

**Behnood Bikdeli, MD, MS**

New York-Presbyterian Hospital/ Columbia University Irving Medical Center

622 West 168th St, PH 3-347, New York, NY 10032

Phone/ Fax: 212-305-6354

Email: [bb2813@cumc.columbia.edu](mailto:bb2813@cumc.columbia.edu), [Behnood.bikdeli@yale.edu](mailto:Behnood.bikdeli@yale.edu)

Twitter handle: @bbikdeli

**Mahesh Vasantha Madhavan, MD**

New York-Presbyterian Hospital/ Columbia University Irving Medical Center

622 West 168th St, PH 3-347, New York, NY 10032

Phone/ Fax: 212-305-6354

Email: [mvm2122@cumc.columbia.edu](mailto:mvm2122@cumc.columbia.edu)

Twitter handle: @MVMadhavanMD

**ABSTRACT**

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19 associated thrombotic disease. In this manuscript by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.

**KEYWORDS**: Coronavirus disease 2019, thrombosis, inflammation, fibrinolytic therapy, anticoagulation, immunomodulator, antithrombin, thrombomodulin

**INTRODUCTION**

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic.(1, 2) SARS-CoV-2, which is responsible for coronavirus disease 2019 (COVID-19), can cause pneumonia and acute respiratory distress syndrome (ARDS) as well as a number of extrapulmonary manifestations. These include cardiovascular, hematologic, and thrombotic sequelae due to direct and indirect effects of the viral illness.(3-5) Indeed, the limited data available on thrombotic complications in patients with COVID-19 suggest that rates of venous thromboembolic events may be as high as 25% to 30%, particularly in critically ill, mechanically-ventilated patients.(6-8) Thrombotic complications also include stroke, acute limb ischemia, and acute coronary syndromes.(9-11)

Limited data are available to determine the antithrombotic therapy to improve outcomes in patients with COVID-19 who do not have confirmed evidence of thrombosis. The optimal dose and agent for thromboprophylaxis remain unknown. Conservative management has merit based on historical data pertaining to critically-ill medical patients (12) as well as for COVID-19-specific escalation of treatment.(13) For interim decision-making, consensus-based guidance has been provided by some groups (14-17), including the Global COVID-19 Thrombosis Collaborative Group (5) (Table 1). However, unlike other extensively studied illnesses such as sepsis,(18) a comprehensive assessment of potential options for prevention of thrombosis in various subgroups of patients with COVID-19 has not to date been proposed.

In this manuscript, prepared by the Global COVID-19 Thrombosis Collaborative Group, we summarize potential therapeutic options for prevention of thrombosis in COVID-19 patients *in the absence of confirmed thrombotic events*. Our focus is on novel approaches to dosing commonly used antithrombotic agents (heparin-based regimens and direct oral anticoagulants (DOACs)), considerations for empiric use of less widely used antithrombotic drugs such as danaparoid, and the potential applications of antiplatelet agents. In addition to the direct antithrombotic effects, other mechanisms of action—including anti-inflammatory or antiviral effects—have been postulated.(19, 20) Finally, we discuss other therapies, such as immunomodulators, that may have antithrombotic properties. The goal is not to provide immediately actionable management recommendations (as high-quality data to reliably inform such guidance in patients with COVID-19 are lacking), but rather to summarize potential treatment options and their advantages and limitations for ongoing and future investigations. We outline research priorities for these agents across the relevant clinical subgroups.

**METHODOLOGICAL CONSIDERATIONS**

To provide a thorough assessment for the rationale and potential advantages and limitations of various antithrombotic agents, sub-committees from the collaborative drafted the sections focused on specific agents, and these sections were then reviewed and revised by the entire group. The co-lead authors searched MEDLINE (with PubMed interface) to ensure that no other high-quality clinical study was missed (date of last search: May 5, 2020).

For research priority setting, a survey was sent to the group of coauthors who were asked to rate the overall priority for investigating each of the discussed agents and to identify the care setting wherein the investigation was most reasonable (outpatients with COVID-19, inpatients on the wards, critically-ill patients in the intensive care unit, or patients post-hospital discharge).

**INVESTIGATIONAL STRATEGIES TARGETING THROMBO-INFLAMMATION IN COVID-19**

In the subsequent sections, we describe various investigational strategies for anticoagulants, antiplatelet agents, hemostatic modulating agents, and immunomodulators that may have potential for further investigation for patients with COVID-19 (Tables 2, 3 and Figure 1). In addition, a summary of the survey results for research priorities with these agents is provided in Table 4 and Figures 2 and 3.

**Anticoagulants**

***Unfractionated heparin and low-molecular-weight heparins.*** Unfractionated heparin and low-molecular-weight heparins are the most frequently administered parenteral anticoagulants.(21) In addition to their antithrombotic activity, they have postulated anti-inflammatory and anti-viral properties. Their anti-inflammatory properties may occur through selectin blockade, inhibition of bradykinin and thrombin generation, and binding of inflammatory cytokines.(22, 23) Heparins may also possess anti-viral properties. For example, heparin may attenuate viral interaction with the ACE2 receptor by binding SARS-CoV-2 spike protein.(24)

The use of empiric heparin anticoagulation in patients with H1N1 ARDS was associated with reduced risk of thrombotic events without an increase in bleeding complications.(25) With this consideration and the concern for breakthrough rates of thrombotic events despite prophylactic anticoagulation,(7) a number of randomized trials evaluating varying intensities of heparin-based anticoagulation, ranging from prophylactic, or weight-adjusted prophylactic dose treatment to intermediate to full-dose therapy are underway (NCT04345848, NCT04344756, NCT04373707, NCT04359277, NCT04367831, NCT04362085, NCT04377997). Additionally, several institutions have implemented protocols to initiate therapeutic anticoagulation empirically, utilizing risk stratification based on an individual’s thrombotic and bleeding risk.(26, 27) Future prospective studies are needed to evaluate the use of these strategies on thrombotic and bleeding complications.

One potential challenge in the use of unfractionated heparin is the utility of the activated partial thromboplastin time (aPTT) for monitoring heparin. In patients with COVID-19, besides the intensity of heparin-based regimens, substantial heterogeneity in the aPTT response may be driven by high levels of factor VIII and fibrinogen, or the presence of a lupus anticoagulant.(28, 29) Consequently, anti-factor Xa levels may need to be measured to ensure that a therapeutic heparin level is achieved.(30)

Trials of inhaled heparin for treatment of COVID-19 are being planned to disrupt SARS-CoV-2 and its ACE2 receptor interaction. Docking of the virus to host cells is mediated by the interaction between the spike (S) protein and heparan sulphate chains of proteoglycans. This facilitates further binding of SARS-CoV-2 to its cell-surface receptor, angiotensin converting enzyme 2 (ACE2), via the surface unit (S1) of its S protein (31, 32). It is known that heparin can displace surface proteoglycans, prevent SARS-CoV-2 entry into human cells.(20, 33) Drug-drug interactions between COVD-19 investigational therapies and antithrombotic agents should be also considered. Table 2 provides a graphical summary of potential interactions.

***Danaparoid.***Danaparoid (a mixture of sulfated glycosaminoglycans including heparan sulphate, dermatan sulphate, and chondroitin sulphate) attenuates thrombin generation by catalyzing the inhibition of factor Xa by antithrombin and thrombin by antithrombin and heparin cofactor II.(34) Currently, danaparoid is predominantly used in patients with heparin-induced thrombocytopenia in several countries other than the United States.

ARDS is associated with dysregulated inflammation and coagulation.(5, 35, 36) Patients with ARDS have an increased risk of VTE as well as thrombocytopenia,(37) renal failure, and bleeding.(38) Because of its safety profile in patients with heparin-induced thrombocytopenia, its minor effects on platelet function(39) (particularly in sepsis(40)), and potential for management of disseminated intravascular coagulation (DIC),(34, 41) danaparoid appears to be an attractive option for research in critically-ill patients with COVID-19. Importantly, however, no reversal agent is available in the setting of bleeding complications.

Thrombi have been noted in the pulmonary arteries and vessels of other organs including the liver and kidneys in patients having died of COVID-19. The presence of these in situ thrombi raises the possibility that widespread endothelial activation in COVID-19 triggers thrombosis.(42, 43) In animal models of sepsis, danaparoid reduces cytokine levels and attenuates thrombosis.(44, 45) Intra-alveolar deposits of fibrin and activated leukocytes also contribute to the respiratory failure in patients with COVID-19 pneumonia. Danaparoid can be nebulized has been shown to attenuate pulmonary coagulopathy, systemic coagulation, pulmonary inflammation, and improve survival in a lung injury model.(46) Nebulized danaparoid administration may concentrate its effect on the lungs and decrease the risk of systemic adverse reactions. Although danaparoid is being empirically used in some centers, no published report or registered clinical trials exist for its use in COVID-19.

***Other parenteral anticoagulants.***Parenteral anticoagulants such as bivalirudin, argatroban, and fondaparinux have been studied in management of patients with acute coronary syndromes, venous thromboembolism and heparin-induced thrombocytopenia (47, 48). However, these agents are more expensive than unfractionated heparin or LMWH, and there are limited data about their use in COVID-19.

***Vitamin-K Antagonists (VKAs).*** VKAs, including warfarin, function by inhibiting vitamin K epoxide reductase, which results in the prevention of the recycling of vitamin K epoxide back to its active form (49). The active form of vitamin K is essential for synthesis of clotting factors in the coagulation cascade (e.g. II, VII, IX, and X) and anticoagulant factors (proteins C and S) (49), and so vitamin K antagonists result in reduction of these factors. These drugs are used for treatment of established thrombotic events (e.g. deep venous thrombosis or pulmonary embolism) or for prophylaxis in patients with specific indications (e.g. atrial fibrillation and prosthetic mechanical heart valves). However, in the course of COVID-19 there are several challenges with use of VKAs, including drug-drug interactions, and need for international normalized ratio monitoring, as described previously (5). There are currently no active studies evaluating the use of vitamin K antagonists in COVID-19.

***Direct oral anticoagulants.*** Beyond their anticoagulant effects, direct oral anticoagulants (DOACs), especially factor Xa inhibitors, may exert anti-inflammatory effects in COVID-19.(50) As has been demonstrated with rivaroxaban, DOACs can prevent arterial and venous thrombosis in patients with history of acute coronary syndrome,(51) stable atherosclerotic vascular disease,(52) or peripheral artery disease undergoing revascularization.(53) Rivaroxaban and betrixaban reduce the risk of venous thromboembolism in medically ill patients.(54-56) As such, there is interest in administering DOACs to patients with severe COVID-19. These benefits should be weighed against the increased risk of bleeding events.

DOACs offer the potential for in-hospital and post-hospital VTE prophylaxis. Results of studies with DOACs for extended prophylaxis in medically ill patients without COVID-19 have been mixed.(54, 57) However, recent investigations in patients who are at high risk for VTE and low risk for bleeding (including those with severe infection) have demonstrated a net clinical benefit, especially for extended thromboprophylaxis post-hospital discharge with betrixaban or rivaroxaban.(54, 58) There is currently one registered clinical trial (C-19-ACS) assessing low-dose rivaroxaban along with dual antiplatelet therapy, statins, and a proton pump inhibitor in patients with COVID-19 and a suspected acute coronary syndrome (NCT04333407).

A few centers have integrated DOACs into VTE prophylaxis algorithms for both in-hospital and post-discharge care.(27) However, concerns remain about DOAC use in patients with COVID-19–associated complications, including its renal clearance and acute renal insufficiency, need for invasive procedures (e.g., dialysis access), extracorporeal membrane oxygenation, and difficultly in administering reversal agents.(59, 60) Finally, drug–drug interactions need to be considered when using DOACs with some investigational COVID-19 therapies (see Table 2).(61) A recent small study showed increased adsorption with high drug levels of DOACs in patients with COVID-19 who received antiviral agents.(62) DOACs may offer an attractive option to prevent thromboembolic events in the pre-hospitalization period for high risk patient groups with COVID-19, such as those with underlying cardiovascular disease or high VTE risk factors. There is at least one planned study with rivaroxaban underway in outpatients with COVID-19 (Prevent HD).

In patients with high suspicious for VTE, diagnosis should be sought when possible. For empiric treatment of select patients in whom presumed VTE events cannot be confirmed during the hospitalization period, for logistical reasons, use of DOACs upon hospital discharge offers additional convenience.(63) Delayed VTE imaging does not have sufficiently high negative predictive value to exclude an earlier event. Challenges with this approach include the uncertainty in the diagnosis of VTE, and that delayed VTE imaging may not have sufficiently high negative predictive value to exclude an earlier event. Some COVID-19 patients will not be candidates for DOACs, such as those with severe renal dysfunction, mechanical heart valves, and antiphospholipid syndrome, or those taking antiviral or immunomodulatory medications that may be associated with drug–drug interactions, and poor medication adherence.

**Sulodexide**

Sulodexide is an orally administered purified glycosaminoglycan consisting of heparan sulfate (80%) and dermatan sulfate.(64) It exerts antithrombotic properties through reduction of fibrinogen (65, 66) and plasminogen activator inhibitor-1 (PAI-1) (65, 67) and is thought to have anti-inflammatory properties.(66, 68, 69) In a recent systematic review of randomized trials across a variety of cardiovascular indications, use of sulodexide compared with control was associated with reduced risk of VTE, myocardial infarction, cardiovascular mortality, and all-cause mortality. (70) Despite the potential interest, limited data exist about the safety and efficacy of sulodexide in patients with COVID-19 and there are currently no registered trials for sulodexide in these patients.

**Fibrinolytic (thrombolytic) agents**

***Systemic fibrinolytic therapy.*** Systemic fibrinolytic (thrombolytic) therapy is approved for management of ST-segment elevation myocardial infarction, ischemic stroke, and high-risk pulmonary embolism. Off-label use has been reported for the treatment of a small number of severely ill patients with ARDS secondary to COVID-19 (71-73). While empiric use of fibrinolytic agents is not based on solid clinical evidence and confers significant bleeding risk, there is precedent for its use in ARDS. As with other causes of ARDS, fibrin-rich hyaline membranes have been reported in lung biopsy specimens from patients with COVID-19 (74). Additionally, D-dimer, prothrombin time, and fibrinogen levels may all be increased in COVID-19 patients with significant lung involvement (75), suggesting derangement of coagulation. The presence of microthrombi in the pulmonary microcirculation has been implicated as a possible mechanisism for clinical deterioration (76).

Fibrinolytic agents such as urokinase and tissue-type plasminogen activator have reduced the risk of ARDS in porcine models (77). Similarly, lung-protective findings have been noted in murine models (78). A meta-analysis of pre-clinical studies corroborated these findings in various animal models(79). Anecdotal reports have noted improvement in oxygenation and ventilation parameters (80). A recent small study (n=60) study found improvement in surrogate parameters of ventilation and a reduction in ICU-mortality in patients with severe non-COVID-19-related ARDS treated with inhaled streptokinase (81).

The bleeding risks of fibrinolysis must be balanced against these pre-clinical data and small human series. Systemic fibrinolysis has been associated with a 1-3% rate of intracranial hemorrhage and notable risk of other forms of major bleeding across a wide span of acute diseases.(82-84) Additionally, there is concern for diffuse alveolar hemorrhage after fibrinolysis, though reports of this complication have yet to be reported. Prior studies have suggested fibrinolytic agents such as alteplase can be associated with prolonged hypofibrinogenemia.(85)

Based on the present evidence utilization of fibrinolysis for COVID-19–associated ARDS, even when severe, cannot uniformly be recommended given its unknown risk–benefit ratio. However, investigational use of fibrinolytic agents in carefully selected patients may be considered. A Phase 2a randomized trial is underway to test the hypothesis whether systemic tissue-type plasminogen activator results in an improvement of respiratory function/oxygenation and reduction in mortality (NCT04357730). Further, inhaled fibrinolytic agents are an interesting option, potentially limiting systemic complications.(86) Assessment of their safety and efficacy requires further investigation (NCT04356833).

**Antiplatelet Agents**

***Aspirin.*** Dysregulated immune response and abnormal coagulation are common occurrences in the pathophysiology of viral sepsis, ARDS, and organ failure in COVID-19.(87) Platelets play a key role in the pathogenesis of sepsis and thrombosis, and are a potential target for prevention of the complications.(88)

In addition to thrombosis and hemostasis, platelets have immunomodulatory activity, including both inflammatory and anti-inflammatory responses, as well as antimicrobial host defense(89, 90). There is evidence that the initial intrinsic defense against infections is mediated by platelet–neutrophil cross-communication that tightly regulates immune and complement responses.(89) These interactions can facilitate a variety of proinflammatory effects such as cytokine release, endothelial cell activation, platelet-leukocyte interaction, formation of neutrophil extracellular traps, and fibrin/microthrombus formation that while potentially harmful (61, 91) can also inhibit macrophage-dependent inflammation and thus may on balance be protective.(88),(92, 93)

Acetylsalicylic acid (aspirin) has been extensively studied in ARDS. Aspirin has been associated with ARDS prevention and higher survival rates from acute lung injury in animal models and observational human studies.(94-99) Aspirin has been associated with reduced mortality in the setting of both pre-hospital use and use in ICU.(97, 98) These findings, however, were not validated in a phase 2b randomized clinical trial.(100) Some investigators have hypothesized that higher maintenance doses of aspirin (325 to 650 mg/d) may be required to achieve the desired anti-inflammatory effect in patients with an exuberant immune response.(101, 102)

***P2Y12 receptor antagonists*.** The role of P2Y12 receptor inhibitors has also been described in ARDS and sepsis. Adenosine diphosphate-mediated activation of the P2Y12 receptormay occur in many inflammatory and immune cell types including platelets, leukocytes, and dendritic cells. Among 224 consecutive patients admitted for community-acquired pneumonia, those receiving antiplatelet agents (aspirin and/or thienopyridines) for at least 6 months had lower use of the ICU and shorter stay in the hospital compared with age-matched controls.(103) In a post-hoc analysis from the PLATO trial, patients with acute coronary syndromes treated with the potent P2Y12 inhibitor ticagrelor and aspirin had fewer adverse pulmonary events and sepsis and lower mortality with those events compared with patients treated with the less potent P2Y12 inhibitor clopidogrel and aspirin.(104)

The XANTHIPPE trial (Examining the Effect of Ticagrelor on Platelet Activation, Platelet-Leukocyte Aggregates, and Acute Lung Injury in Pneumonia) was the first double-blind, placebo-controlled, randomized study to evaluate the effect of ticagrelor on inflammation, platelet activation, and lung function in patients with community or hospital-acquired pneumonia.(105) Among 60 randomized patients, ticagrelor administration within 48 hours of pneumonia diagnosis was associated with an anti-inflammatory effect evidenced by reduced platelet-leukocyte aggregates in the circulation, lowered interleukin-6 levels, and improved lung function with a decrease in supplemental oxygen requirements. However, given the potential bleeding, risks, in the absence of phase III trials demonstrating favorable clinical outcomes, these research findings have not translated into routine clinical practice.

With respect to COVID-19 and antiplatelet agents, there are many unknowns as regards their use and utility. First, it is not clear which phase of the disease might best respond. Second, the optimal agent and dose to maximize efficacy while minimizing bleeding risks are unknown. Due to its pleiotropic effects, ticagrelor may have more potent anti-inflammatory and even bactericidal characteristics than other agents.(106, 107) Randomized trials evaluating role of aspirin and clopidogrel in COVID-19 patients at increased cardiovascular risk are underway (NCT04333407). Third, antiplatelet therapies may have adverse drug–drug interactions with some investigational COVID-19 therapies such as lopinavir/ritonavir and remdesivir.(5, 108, 109) Fourth, thrombocytopenia (immune-mediated or consumption-related) is associated with increased risk for worse clinical outcomes with COVID-19.(110, 111) Finally, the extent to which bleeding risks are increased, particularly in patients with disseminated intravascular coagulation, is unknown.

***Dipyridamole*.** Dipyridamole is a phosphodiesterase inhibitor that inhibits platelet aggregation by increasing intracellular concentrations of cAMP.(112) In addition to its well-known antithrombotic properties, dipyridamole may have antiviral effects with proposed activity against influenza in animal models.(113) In mouse models of viral pneumonia, dipyridamole administration promoted interferon response and prolonged survival in infected mice. Dipyridamole has antiviral effects *in vitro*, specifically confirming the affinity of dipyridamole for a SARS-CoV-2 main protease (Mpro).(114) To date, one study has examined dipyridamole in the treatment of COVID-19; 31 patients with COVID-19 were randomized to dipyridamole (150 mg tid for 7 days) versus control. In this small study those treated with dipyridamole showed trends toward higher cure and hospital discharge rates. Increased platelet counts and decreased D-dimer levels were also noted with dipyridamole treatment, attributed to infection resolution.(115) Further high-quality data are needed to evaluate the anti-SARS-CoV-2 therapeutic potential of dipyridamole.

***Vorapaxar.***Vorapaxar is an antiplatelet agent that exerts its antiplatelet activity through reversal antagonism of the protease-activated receptor 1 (PAR-1) and inhibition of thrombin induced platelet aggregation.(116) In patients with history of myocardial infarction, or peripheral arterial disease, vorapaxar has been shown to reduce thrombotic cardiovascular events.(117) The main concern associated with vorapaxar is its increased risk of bleeding events and reports of intracranial hemorrhage in patients with a previous history of stroke. PAR-1 is thought to have an important role in thrombin-induced platelet aggregation, and the link between coagulation, inflammation, and the fibrotic response. As such, investigating vorapaxar in patients with COVID-19 has received some attention.(50) However, its terminal half-life of 8 days renders it difficult to use in patients with severe COVID-19. To date, there are no registered randomized trials for use of vorapaxar in patients with COVID-19.

**Hemostatic Modulating Agents**

***Antithrombin.***The single-chain glycosaminoglycan antithrombin, which is produced in the liver, is modestly decreased in patients hospitalized with COVID-19.(118, 119) Thus, reduced antithrombin may be a potential therapeutic target for patients with COVID-19. Furthermore, the -isoform of antithrombin binds preferentially to vascular heparin sulfate proteoglycans and initiates prostacyclin production and inhibition of NF-B, resulting in anti-inflammatory effects, which might be further pronounced by the binding of -antithrombin to receptors on monocytes.(120) Limited supporting data exist from patients with severe acute respiratory syndrome (SARS). Compared with healthy individuals such patients had lower levels of the natural inhibitors of coagulation and higher levels of plasminogen activator inhibitor type 1 (PAI-1).

Blood coagulation parameters were investigated in 94 patients with COVID-19 pneumonia, of whom 49 had “ordinary”, 35 had severe, and 10 had critical forms of COVID-19.(121) When compared with 40 healthy controls, patients in all 3 categories of COVID-19 had significantly lower levels of antithrombin, and the 3 subsets of patients had similar levels (86.0%, 85.6%, and 82.4%). Nebulized antithrombin has resulted in decreased coagulopathy and inflammation in animal models of lung injury.(122-124) Despite these promising findings, there is to date no clinical evidence to support antithrombin provision to critically ill patients or in those with DIC and COVID-19. In a randomized controlled trial of 2314 patients with severe sepsis, there was no effect of antithrombin therapy on 28-day mortality.(125) Moreover, in a meta-analysis of 3019 patients included in 11 trials, antithrombin administration in critically ill patients was associated with more bleeding events (relative risk: 1.58; 95% CI 1.35 to 1.84).(126)

***Thrombomodulin*.** Thrombomodulin is an endothelial cell glycoprotein with potent anticoagulant and anti-inflammatory effects mediated through activated protein C (APC)-dependent and APC-independent protein C mechanisms. In inflammatory states, thrombomodulin production is downregulated and surface thrombomodulin is cleaved so that there is reduced activation of Protein C. (127) The role of recombinant thrombomodulin as a potential modifier of clinical outcomes in patients with sepsis has been evaluated in clinical trials.

The SCARLET study (Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin) was a randomized placebo-controlled double blind study of recombinant human soluble thrombomodulin (rhsTM) in 800 patients with objective evidence of bacterial infection, sepsis-induced systemic inflammatory response syndrome, and concurrent cardiovascular and/or respiratory dysfunction.(128) There was no significant between-group differences in the 28-day primary mortality outcome or other secondary endpoints. A post-hoc subgroup analysis in patients with coagulopathy reported a trend for reduced mortality compared with placebo (risk difference -5.40%; 95% CI −1.68% to 12.48%). A subsequent systematic review and meta-analysis suggested lower mortality among patients with (but not in those without) sepsis-induced coagulopathy treated with thrombomodulin (RR: 0.80; 95% CI, 0.65-0.98).(129) Currently there is insufficient evidence to recommend the routine s use of thrombomodulin in patients with severe COVID-19. However, investigational use is warranted in selected subgroups with evidence of coagulopathy.

***Activated protein C (APC).***APC can play a key role in reducing the damage caused by wide variety of triggers, including ischemia/reperfusion injury, gastrointestinal inflammation, sepsis, and Ebola virus infection.(130) In 2002, recombinant human protein C was approved by the US Food and Drug Administration for the clinical treatment of severe sepsis and ARDS. Protein C concentrates reduced the risk of mortality in early studies of sepsis and septic shock. However, subsequent clinical trials have reported neutral results.(18) Specifically, a randomized trial of 1697 patients did not demonstrate a reduction in mortality at 28 or 90 days after APC was administered in the setting of septic shock (131), and subsequent concerns emerged regarding the risk of serious bleeding and death in individuals with bleeding precautions (132). A possible explanation is that APC may only benefit septic patients complicated by DIC, which was a minority of patients in these trials.

In a study of 27 patients with ARDS (16 treated with recombinant APC and 11 with placebo), the infusion of recombinant APC increased APC levels in the pulmonary compartment and attenuated systemic coagulopathy and pulmonary coagulopathy, providing faster resolution of pulmonary dysfunction without bleeding complications(133). However, in a subsequent randomized controlled trial of 71 patients, infusion of recombinant APC for infectious or inflammatory ARDS did not improve alveolocapillary permeability nor the clinical course of ARDS patients.(134)

It is intuitive that protein C concentrates may be more beneficial in paitents with significant protein C reduction. However, in a small study of 11 critically-ill COVID-19 patients, protein C levels were overall increased, with only 4 patients having a protein C level lower than normal.(119) The protein C mutant, 3K3A‐APC, being developed for acute stroke treatment, was engineered to have low anticoagulant activity (so low bleeding risk) while retaining APCs anti-inflammatory and cytoprotective cell signaling properties that may be important in pneumonia. The potential utility of recombinant APC or 3K3A‐APC in patients with COVID-19, including those with DIC, is worthy of prospective investigation.(135)

***Contact Activation System.*** Dysregulation of inflammation and coagulation are hallmarks of COVID-19. The contact activation system, which includes factor XII, factor XI, high-molecular-weight kininogen, and prekallikrein, links inflammation and coagulation by triggering the generation of thrombin and bradykinin. Thrombin promotes clot formation and platelet activation, whereas bradykinin induces the release of proinflammatory cytokines.

In nonhuman primate models of bacterial sepsis, inhibition of factor XIIa or blockade of reciprocal factor XI and factor XII activation reduced the levels of inflammatory cytokines, attenuated microvascular thrombosis, and improved survival.(136-139) Likewise, in murine models of bacterial sepsis, inflammation and coagulation were attenuated, and survival was enhanced in factor XI-deficient mice compared with their wild-type counterparts.(140, 141) Several inhibitors of factor XII and factor XI are currently under investigation. Studies evaluating the efficacy and safety of these agents in COVID-19 are warranted.(142)

**Anti-inflammatory Agents**

***Corticosteroids*.** There is conflicting evidence for the use of corticosteroids in COVID-19-related ARDS.(143) Postulated benefits, including reduction in inflammation and lung injury, must be weighed against the potential risks of delayed viral clearance and increased susceptibility to secondary infections.(144-147)

Mechanisms as to whether corticosteroids may modulate thrombotic risk in this patient population are not well-established. As the microvascular and macrovascular thrombotic complications observed in COVID-19 may in part be attributable to the inflammatory environment precipitated by the infection, corticosteroids may reduce thrombotic risk through anti-inflammatory activity. Studies of inflammatory states, particularly rheumatologic conditions, have shown a proportional relationship between inflammatory activity, coagulability, and the risk of VTE. Results regarding frequency of thrombosis with disease-modifying therapies, including corticosteroids, are mixed.(148, 149) Possible beneficial (150)mechanisms include reductions in levels of procoagulant factors, including fibrinogen and von Willebrand factor.(151) However, experimental studies have also linked steroid use to increased levels of various clotting factors, and several large-scale studies have shown exogenous glucocorticoids to be a risk factor for thrombosis.(150-152) Prior studies of corticosteroids in patients with non-COVID-19-related ARDS have shown mixed results with potential benefit limited to only certain subgroups of patients (153). Further experience and research, including results from a series of ongoing randomized trials, are needed to better understand the balance of pro- and anti-coagulant properties of glucocorticoids in the setting of COVID-19.

***Hydroxychloroquine*.** Hydroxychloroquine is a 4-aminoquinoline that has an immunomodulatory effect and antithrombotic activity that have been demonstrated in animal models and in patients with systemic lupus erythematosus, rheumatoid arthritis, and antiphospholipid syndrome.(154-157)

In a mouse model, hydroxychloroquine reversed the thrombogenic properties of antiphospholipid antibodies.(158) Hydroxychloroquine may also have mild antiplatelet effects in patients with antiphospholipid antibodies, and may reduce blood viscosity.(154) An observational prospective study of patients with antiphospholipid antibody syndrome treated with hydroxychloroquine 200 mg daily demonstrated significant reduction in soluble tissue factor levels at 3 months compared to baseline.(159) Other potential antithrombotic mechanisms have led to its limited evaluation as a thromboprophylaxis modality in postoperative patients more than three decades ago.(160, 161) However the exact mechanisms by which it exerts it antithrombotic effect remain largely unknown. Given the known adverse effects with hydroxychloroquine, including QTc prolongation and risk of arrhythmias,(162) its routine use as an antithrombotic therapy in patients with COVID-19 cannot be recommend until further prospective data emerge.

***Statins.*** HMG-CoA reductase inhibitors (statins) are widely used as cholesterol-lowering medications in patients with or at increased risk of atherosclerotic cardiovascular disease.(163) The pleiotropic effects of statins include improving endothelial function, decreasing inflammatory markers, and inhibiting thrombogenicity.(164) Because patients with COVID-19 may exhibit increased activation of the inflammatory cascade and are prone to venous and arterial thrombosis, leveraging statins as a component of treatment has been proposed.(5, 165, 166)

While no clinical studies have evaluated statin therapy in the management of COVID-19, there is biological plausibility and precedent for such investigation. Through inhibition of the MYD88 stress-response pathway, statins suppress NF-kB–induced proinflammatory cytokines.(167) This may underlie their proposed utility in other viral pneumonias, including those caused by related coronaviruses.(168-170) Besides mitigating inflammation, antiplatelet and anticoagulant properties can occur via downregulation of tissue factor, upregulation of thrombomodulin, and inhibition of thromboxane A2.(171) Prior reports have shown that use of statins is associated with reduced rates of VTE, and statins have stabilizing effects on atherosclerotic plaques.(172, 173) At least three clinical trials (NCT04348695, NCT04333407, and NCT04343001) are recruiting COVID-19 patients in randomized statin investigations.

**Targeted Immunomodulatory Therapies.** SARS-CoV-2 infection is associated with an inflammatory response marked by increased cytokine levels (e.g. IL-2, IL6, IL-10, TNF-α).(174) In order to treat the inflammatory response generated by severe COVID-19, some have proposed to repurpose immunomodulatory medications approved for other diseases.

One potential target is the complement cascade. A major component of innate immunity, the complement cascade has three independent pathways for activation (classical, lectin, and alternative), each culminating with formation of the lytic membrane attack complex. Eculizumab is an anti-C5 monoclonal antibody that blocks terminal complement activity. One of its clinical applications is complement-mediated thrombotic microangiopathy, namely atypical hemolytic uremic syndrome, which is thought to occur in some patients with COVID-19.(19, 175) In one study of 5 COVID-19 non-survivors, there was evidence of systemic activation of the alternative and lectin-based complement pathways and deposition of the membrane attack complex in both lung and skin.(175)

Based on these data and evidence of efficacy of complement inhibition in murine models of SARS-CoV and MERS-CoV, the use of eculizumab in COVID-19 has been proposed.(36, 175, 176) Potential barriers include a 1000-2000 times increased risk of meningococcal disease (requiring prior vaccination or antibiotic prophylaxis) and cost ($20,000-$25,000 per dose). The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is another potential therapeutic target. JAK inhibitors target cytokine signaling pathways and have thus been proposed as a candidate to treat COVID-19.

In addition, JAK inhibitors target cytokine signaling pathways and have thus been proposed as a candidate to treat COVID-19. Baricitinib, a JAK1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis, mitigates the systemic inflammatory response and has *in vitro* activity against SARS-CoV-2 through its numb-associated kinase inhibition that has a high affinity for AAK1, a regulator of clathrin-mediated endocytosis.(177) Notably, this therapy does carry a FDA warning for an increased incidence of venous thromboembolism (6/997 patients with baricitinb vs. 0/1,070 controls),(178) and recent National Institute of Health (NIH) COVID-19 Treatment Guidelines recommends against the use of baricitinib outside of a clinical trial, such as the National Institute of Health sponsored ACTT-2 trial comparing remdesivir ± baricitinib.(179) Ruxolitinib is a JAK2 inhibitor approved for patients with myelofibrosis and polycythemia vera. Similar to baricitinib,(180-182) ruxolitinib presently under investigation as a treatment for COVID-19.(25, 183-187)

Tocilizumab, an IL-6 receptor antagonist approved for the treatment of rheumatoid arthritis and cytokine release syndrome associated with chimeric antigen receptor-T cell therapy, is included in the Chinese National Health commission guidelines for treating COVID-19. While findings are yet to be published, a randomized trial of 129 hospitalized patients with moderate-to-severe COVID-19 pneumonia suggested that tocilizumab administration may significantly reduce rates of death or life support interventions (188). It is thought that tocilizumab may mitigate the pro-atherothrombotic profile associated with rheumatoid arthritis. However, no specific data related to use of tocilizumab and VTE events in patients with COVID-19 have been published.

**FUTURE DIRECTIONS AND CONCLUSIONS**

Despite the efforts of the international medical and scientific communities and recent declines in hospitalizations, COVID-19 continues to pose an unprecedented challenge. The prognosis for hospitalized patients with COVID-19, especially in the setting of critical illness, continues to be poor (11, 189). While contributing factors to poor outcomes in patients with COVID-19 are likely multifactorial, thrombotic complications play a major role in the prognosis of these patients (5). The development of safe and effective thromboprophylaxis and treatment strategies for thrombotic disease is contingent on an improved understanding of the mechanistic and pathophysiologic basis for such complications in COVID-19 patients. In this document, we have outlined a number of agents and mechanisms of action for potential for use as antithrombotic agents in the setting of COVID-19. Survey results from group of authors may be helpful for research priority settings for various agents and patient subgroups with COVID-19 (Table 4). High-quality research investigations into the optimal drug, dose, and duration of therapies to prevent and treat thrombotic complications of COVID-19 offer the potential to improve outcomes of infected patients.

**DISCLOSURES**

Team, please add your Disclosures.

Dr. Bikdeli reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to a specific type of IVC filters.

Dr. Madhavan reports being supported by an institutional grant by the National Institutes of Health/ National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center (T32 HL007854).

Dr Bertoletti reports personal fees and non-financial support from ASPEN, BAYER, LEO-PHARMA, BMS-PFIZER, and non-financial support from DAIICHI, outside the submitted work.

Dr. Jimenez reports no conflicts of interest.

Dr. Ageno has received honoraria from Boehringer Ingelheim, Bayer Pharmaceuticals, BMS-Pfizer, Daiichi-Sankyo, Aspen, Sanofi, Portola, Janssen. Research support from Bayer Pharmaceuticals.

Dr. Dimakakos receives consulting fees from Sanofi and Leo.

Dr. Sehgal has no Disclosures.

Dr. Sethi reports honoraria from Janssen and Chiesi, Inc.

Dr Quéré has received honoraria as a speaker from Bayer Pharmaceuticals, BMS-Pfizer, Leo Pharma and Aspen.

Dr. Favaloro has nothing to disclose.

Dr Tafur: Recovery Force: Consultancy; Janssen: Other: Educational Grants, Research Funding; BMS: Research Funding; Idorsia: Research Funding; Daichi Sanyo: Research Funding; Stago: Research Funding; Doasense: Research Funding.

Dr. Fareed has no disclosures.

Dr. Cushman has nothing to disclose.

Dr Eikelboom has received consulting fees and/or honoraria and grants and/or in-kind support from Astra-Zeneca, Bayer Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis, Servier.

Dr. Gibson reports grants and personal fees from Portola, grants and personal fees from Johnson & Johson, grants and personal fees from Janssen, grants and personal fees from Bayer, grants from BMS, during the conduct of the study; grants and personal fees from Angel Medical Corporation, personal fees from Bayer Corp., grants and personal fees from CSL Behring, grants and personal fees from Janssen Pharmaceuticals, grants and personal fees from Johnson & Johnson Corporation, personal fees from The Medicines Company, personal fees from Boston Clinical Research Institute, personal fees from Cardiovascular Research Foundation, personal fees from Eli Lilly and Company, personal fees from Gilead Sciences, Inc., personal fees from Novo Nordisk, personal fees from Web MD, personal fees from UpToDate in Cardiovascular Medicine, personal fees from Amarin Pharma, personal fees from Amgen, personal fees from Boehringer Ingelheim , personal fees from Chiesi, personal fees from Merck & Co, Inc. , personal fees from PharmaMar, personal fees from Sanofi, personal fees from Somahlution, personal fees from St. Francis Hospital, personal fees from Verreseon Corporation , personal fees from Boston Scientific, personal fees from Duke Clinical Research Institute, personal fees from Impact Bio, LTD, personal fees from MedImmune, personal fees from Medtelligence, personal fees from Microport, personal fees from PERT Consortium, other from nference, non-financial support from Baim Institute, grants from SCAD Alliance, personal fees from GE Healthcare, personal fees from Caladrius Bioscience, personal fees from CeleCor Therapeutics , personal fees from Thrombolytic Science , personal fees from AstraZeneca, personal fees from Eidos Therapeutics, personal fees from Kiniksa Pharmaceuticals, personal fees from Micodrop, LLC, outside the submitted work .

Dr. Hunt takes no monies from pharmaceutical companies.

Dr Spyropoulos receives consulting fees from Boehringer Ingelheim, Janssen, Bayer, BMS, Portola, Medscape, and the ATLAS Group and research grants from Boehringer Ingelheim, Janssen, and IPRO NY.

Dr. Weinberg reports consulting for Magneto Atherectomy Solutions.

Dr. Piazza receives grants from Bayer, Portola, BMS/Pfizer, Janssen, BTG/EKOS, and Daiichi-Sankyo and consulting fees from Amgen, BMS/Pfizer, Janssen, and Boston Scientific.

Dr Kirtane reports Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for speaking engagements and/or consulting; no speaking/consulting fees were personally received. Personal: Travel Expenses/Meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron.

Dr. Stone has received speaker or other honoraria from Cook, Terumo, QOOL Therapeutics and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme; and has equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, Valfix.

Dr. Goldhaber reports grants from Bayer, grants from Boehringer-Ingelheim, grants from BMS, grants from BTG EKOS, grants from Daiichi Sankyo, grants from Janssen, grants from US National Heart Lung and Blood Institute, grants from Thrombosis Research Institute, personal fees from Bayer, personal fees from Boehringer-Ingelheim, outside the submitted work .

Dr. Parikh reports grants and other from Abbott Vascular, other from Boston Scientific, other from Janssen, other from Medtronic Vascular, other from CSI, other from Philips, grants from Surmodics, grants from TriReme Medical, grants from Shockwave Medical, personal fees from Terumo, personal fees from Abiomed, outside the submitted work .

Dr. Krumholz reports personal fees from UnitedHealth, personal fees from IBM Watson Health, personal fees from Element Science, personal fees from Aetna, personal fees from Facebook, personal fees from Siegfried & Jensen Law Firm, personal fees from Arnold & Porter Law Firm, personal fees from Ben C. Martin Law Firm, personal fees from National Center for Cardiovascular Diseases, Beijing, ownership of HugoHealth, ownership of Refactor Health, contracts from the Centers for Medicare & Medicaid Services, grants from Medtronic and the Food and Drug Administration, grants from Medtronic and Johnson and Johnson, grants from Shenzhen Center for Health Information, outside the submitted work.

Dr. Konstantinides reports research grants from Bayer AG, Boehringer Ingelheim, Actelion Janssen; educational grants from Biocompatibles Group UK - Boston Scientific, Daiichi Sankyo; lecture fees from Bayer AG, Pfizer-Bristol-Myers Squibb, MSD, all outside the submitted work.

Dr. Weitz reports serving as a consultant and received honoraria from Bayer, Janssen, JnJ, BMS, Pfizer, Boehringer Ingelheim, Novartis, Daiichi-Sankyo, Merck, Servier, Anthos, Ionis, and PhaseBio.

**REFERENCES**

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.

2. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available Online: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> (Accessed on March 12 2020).

3. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol 2020.

4. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation 2020.

5. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol 2020.

6. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020.

7. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020.

8. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020.

9. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med 2020.

10. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment Elevation in Patients with Covid-19 - A Case Series. N Engl J Med 2020.

11. Bellosta R, Luzzani L, Natalini G, et al. Acute limb ischemia in patients with COVID-19 pneumonia. J Vasc Surg 2020.

12. Akima S, McLintock C, Hunt BJ. RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020.

13. Barrett CD, Moore HB, Yaffe MB, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment. J Thromb Haemost 2020.

14. Zhai Z, Li C, Chen Y, et al. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb Haemost 2020.

15. Vivas D, Roldan V, Esteve-Pastor MA, et al. [Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology]. Rev Esp Cardiol 2020.

16. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus 2020.

17. Casini A, Alberio L, Angelillo-Scherrer A, et al. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis. Swiss Med Wkly 2020; 150: w20247.

18. Murao S, Yamakawa K. A Systematic Summary of Systematic Reviews on Anticoagulant Therapy in Sepsis. J Clin Med 2019; 8(11).

19. Campbell CM, Kahwash R. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? Circulation 2020.

20. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost 2020.

21. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e24S-e43S.

22. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost 2017; 117(3): 437-44.

23. Belen-Apak FB, Sarialioglu F. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Med Hypotheses 2020; 142: 109743.

24. Liu J, Li J, Arnold K, et al. Using heparin molecules to manage COVID-2019. Res Pract Thromb Haemost 2020.

25. Obi AT, Tignanelli CJ, Jacobs BN, et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord 2019; 7(3): 317-24.

26. Obi AT, Barnes GD, Wakefield TW, et al. Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 Pandemic. J Vasc Surg Venous Lymphat Disord 2020.

27. Cohoon KP, Mahé G, Tafur AJ, et al. Emergence of Institutional Antithrombotic Protocols for Coronavirus 2019. Res Pract Thromb Haemost.

28. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006; 96(5): 547-52.

29. Bowles L, Platton S, Yartey N, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med 2020.

30. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012; 32(6): 546-58.

31. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181(2): 271-80 e8.

32. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020.

33. Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One 2011; 6(8): e23710.

34. Dou H, Song A, Jia S, et al. Heparinoids Danaparoid and Sulodexide as clinically used drugs. Prog Mol Biol Transl Sci 2019; 163: 55-74.

35. Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation. Respiration 2017; 93(3): 212-25.

36. Campbell CM, Kahwash R. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? Circulation; 0(0).

37. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost 2015; 41(1): 49-60.

38. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139(1): 69-79.

39. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 1997; 58(4): 279-85.

40. Wolff M, Handtke S, Palankar R, et al. Activated platelets kill Staphylococcus aureus, but not Streptococcus pneumoniae-The role of FcgammaRIIa and platelet factor 4/heparinantibodies. J Thromb Haemost 2020.

41. Minakata D, Fujiwara SI, Hayakawa J, et al. Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis. Acta Haematol 2019: 1-10.

42. Marongiu F, Grandone E, Barcellona D. Pulmonary thrombosis in 2019-nCoV pneumonia? J Thromb Haemost 2020.

43. Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020.

44. Hagiwara S, Iwasaka H, Hidaka S, et al. Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Crit Care 2008; 12(2): R43.

45. Iba T, Miyasho T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care 2008; 12(4): R86.

46. Juschten J, Tuinman PR, Juffermans NP, et al. Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies. Ann Transl Med 2017; 5(22): 444.

47. Bikdeli B, McAndrew T, Crowley A, et al. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thromb Haemost 2020; 120(2): 348-62.

48. Salter BS, Weiner MM, Trinh MA, et al. Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. J Am Coll Cardiol 2016; 67(21): 2519-32.

49. Schein JR, White CM, Nelson WW, et al. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016; 14: 14.

50. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020.

51. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19.

52. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14): 1319-30.

53. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 2020.

54. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368(6): 513-23.

55. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med 2018; 379(12): 1118-27.

56. Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016; 375(6): 534-44.

57. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365(23): 2167-77.

58. Spyropoulos AC, Lipardi C, Xu J, et al. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost 2019; 25: 1076029619886022.

59. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020.

60. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med 2020.

61. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nature Reviews Immunology 2011; 11(4): 264-74.

62. Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost 2020.

63. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315-52.

64. Wu B, Lu J, Yang M, et al. Sulodexide for treating venous leg ulcers. Cochrane Database Syst Rev 2016(6): CD010694.

65. Lasierra-Cirujeda J, Coronel P, Aza M, et al. Use of sulodexide in patients with peripheral vascular disease. Journal of blood medicine 2010; 1: 105-15.

66. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovascular drug reviews 2006; 24(3-4): 214-26.

67. Mauro M, Palmieri GC, Palazzini E, et al. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation. Curr Med Res Opin 1993; 13(2): 87-95.

68. Femiano F, Gombos F, Scully C. Recurrent aphthous stomatitis unresponsive to topical corticosteroids: a study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide. International journal of dermatology 2003; 42(5): 394-7.

69. Bilinska M, Wolszakiewicz J, Duda M, et al. Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study. Medical science monitor : international medical journal of experimental and clinical research 2009; 15(12): CR618-23.

70. Bikdeli B, Chatterjee S, Kirtane AJ, et al. Sulodexide Versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-analysis of Randomized Trials. Semin Thromb Hemost 2020 (In-Press).

71. Doctor gambles on clot-busting drug to save virus patients. Accessible at: <https://apnews.com/5c0dc863f214d32a53c6280c31cf3f56> . Date last accessed: April 20, 2020.

72. Wang J, Hajizadeh N, Moore EE, et al. Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series. J Thromb Haemost 2020.

73. Barrett CD, Morre HB, Moore EE, et al. Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review. Research and Practice in Thrombosis and Haemostasis 2020. <https://doi.org/10.1002/rth2.12357>.

74. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.

75. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020.

76. Moore HB, Barrett CD, Moore EE, et al. Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)? J Trauma Acute Care Surg 2020.

77. Hardaway RM, Williams CH, Marvasti M, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990; 18(12): 1413-8.

78. Stringer KA, Hybertson BM, Cho OJ, et al. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med 1998; 25(2): 184-8.

79. Liu C, Ma Y, Su Z, et al. Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury. Front Immunol 2018; 9: 1898.

80. Hardaway RM, Harke H, Tyroch AH, et al. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg 2001; 67(4): 377-82.

81. Abdelaal Ahmed Mahmoud A, Mahmoud HE, Mahran MA, et al. Streptokinase Versus Unfractionated Heparin Nebulization in Patients With Severe Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial With Observational Controls. J Cardiothorac Vasc Anesth 2020; 34(2): 436-43.

82. Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000; 31(8): 1802-11.

83. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369(9558): 275-82.

84. Chatterjee S, Weinberg I, Yeh RW, et al. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thromb Haemost 2017; 117(2): 246-51.

85. Huang X, Moreton FC, Kalladka D, et al. Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke. Stroke 2015; 46(12): 3543-6.

86. Whyte CS, Morrow GB, Mitchell JL, et al. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost 2020.

87. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020.

88. de Stoppelaar SF, van 't Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 2014; 112(4): 666-77.

89. Koupenova M, Corkrey HA, Vitseva O, et al. The role of platelets in mediating a response to human influenza infection. Nat Commun 2019; 10(1): 1780.

90. de Stoppelaar SF, van 't Veer C, Claushuis TA, et al. Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood 2014; 124(25): 3781-90.

91. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010; 67(4): 525-44.

92. Xiang B, Zhang G, Guo L, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun 2013; 4(1): 2657.

93. Gudbrandsdottir S, Hasselbalch HC, Nielsen CH. Activated platelets enhance IL-10 secretion and reduce TNF-α secretion by monocytes. The Journal of Immunology 2013; 191(8): 4059-67.

94. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116(12): 3211-9.

95. Looney MR, Nguyen JX, Hu Y, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119(11): 3450-61.

96. Wang L, Li H, Gu X, et al. Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis. PLoS One 2016; 11(5): e0154754.

97. Boyle AJ, Di Gangi S, Hamid UI, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Critical Care 2015; 19(1): 109.

98. Chen W, Janz DR, Bastarache JA, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Crit Care Med 2015; 43(4): 801-7.

99. Panka BA, de Grooth HJ, Spoelstra-de Man AM, et al. Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and Meta-Analysis of Clinical Studies. Shock 2017; 47(1): 13-21.

100. Kor DJ, Carter RE, Park PK, et al. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. Jama 2016; 315(22): 2406-14.

101. Kuschner RA. Aspirin and Acute Respiratory Distress Syndrome. Jama 2016; 316(12): 1317-8.

102. Mezidi M, Guerin C. Aspirin for prevention of acute respiratory distress syndrome (ARDS): let's not throw the baby with the water! Ann Transl Med 2016; 4(19): 376.

103. Gross AK, Dunn SP, Feola DJ, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. Journal of thrombosis and thrombolysis 2013; 35(2): 147-54.

104. Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014; 25(7): 517-25.

105. Sexton TR, Zhang G, Macaulay TE, et al. Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia. JACC Basic Transl Sci 2018; 3(4): 435-49.

106. Aungraheeta R, Conibear A, Butler M, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood 2016; 128(23): 2717-28.

107. Lancellotti P, Musumeci L, Jacques N, et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant Gram-positive bacteria. JAMA cardiology 2019; 4(6): 596-9.

108. Itkonen MK, Tornio A, Lapatto-Reiniluoto O, et al. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther 2019; 105(1): 219-28.

109. Marsousi N, Daali Y, Fontana P, et al. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. Clin Pharmacokinet 2018; 57(10): 1347-54.

110. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020.

111. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clinica Chimica Acta 2020.

112. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. British journal of clinical pharmacology 2011; 72(4): 634-46.

113. Tonew E, Indulen MK, Dzeguze DR. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol 1982; 26(3): 125-9.

114. Li Z, Li X, Huang Y-Y, et al. FEP-based screening prompts drug repositioning against COVID-19. bioRxiv 2020: 2020.03.23.004580.

115. Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharmaceutica Sinica B 2020.

116. Baker NC, Lipinski MJ, Lhermusier T, et al. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar. Circulation 2014; 130(15): 1287-94.

117. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366(15): 1404-13.

118. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18(4): 844-7.

119. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost 2020.

120. Rezaie AR, Giri H. Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin. J Thromb Haemost 2020; 18(3): 528-33.

121. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020: <https://doi.org/10.1515/cclm-2020-0188>.

122. Hofstra JJ, Vlaar AP, Cornet AD, et al. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010; 23(2): 105-11.

123. Cornet AD, Hofstra JJ, Vlaar AP, et al. Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats. Shock 2011; 36(4): 417-23.

124. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thrombosis research 1998; 89(5): 233-41.

125. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama 2001; 286(15): 1869-78.

126. Allingstrup M, Wetterslev J, Ravn FB, et al. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2016; 42(4): 505-20.

127. Ito T, Thachil J, Asakura H, et al. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care 2019; 23(1): 280.

128. Vincent JL, Francois B, Zabolotskikh I, et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. Jama 2019; 321(20): 1993-2002.

129. Valeriani E, Squizzato A, Gallo A, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: A systematic review and meta-analysis. J Thromb Haemost 2020.

130. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood 2015; 125(19): 2898-907.

131. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366(22): 2055-64.

132. Gentry CA, Gross KB, Sud B, et al. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009; 37(1): 19-25.

133. Cornet AD, Hofstra JJ, Vlaar AP, et al. Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. J Thromb Haemost 2013; 11(5): 894-901.

134. Cornet AD, Groeneveld AB, Hofstra JJ, et al. Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial. PLoS One 2014; 9(3): e90983.

135. Al-Abdallat MM, Payne DC, Alqasrawi S, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59(9): 1225-33.

136. Lupu F, Keshari R, Silasi R, et al. Blocking activated factsor XII with a monoclonal antibody prevents organ failure and saves baboons challenged with heat-inactivated S. aureus [abstract]. Res Pr Thromb Haemost 2019; 3(Suppl 1): 127-8.

137. Silasi R, Keshari RS, Lupu C, et al. Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death. Blood Adv 2019; 3(4): 658-69.

138. Jansen PM, Pixley RA, Brouwer M, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87(6): 2337-44.

139. Pixley RA, De La Cadena R, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91(1): 61-8.

140. Tucker EI, Verbout NG, Leung PY, et al. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood 2012; 119(20): 4762-8.

141. Luo D, Szaba FM, Kummer LW, et al. Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun 2012; 80(1): 91-9.

142. Shatzel JJ, DeLoughery EP, Lorentz CU, et al. The Contact Activation System as a Potential Therapeutic Target in Patients with COVID-19. Res Pract Thromb Haemost 2020.

143. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. Jama 2020.

144. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.

145. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS medicine 2006; 3(9): e343.

146. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 2018; 197(6): 757-67.

147. Lansbury L, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2: Cd010406.

148. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis research & therapy 2014; 16(5): 435.

149. Zoller B, Li X, Sundquist J, et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379(9812): 244-9.

150. Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013; 173(9): 743-52.

151. van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost 2010; 8(11): 2483-93.

152. Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167(9): 935-43.

153. Khilnani GC, Hadda V. Corticosteroids and ARDS: A review of treatment and prevention evidence. Lung India 2011; 28(2): 114-9.

154. Espinola RG, Pierangeli SS, Gharavi AE, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87(3): 518-22.

155. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13(1): 77-80.

156. Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers 2018; 4: 18005.

157. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69(1): 20-8.

158. Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96(12): 4380-4.

159. Schreiber K, Breen K, Parmar K, et al. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford) 2018; 57(1): 120-4.

160. Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981; 10(2): 89-96.

161. Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med 1988; 85(4A): 57-61.

162. Bessiere F, Roccia H, Deliniere A, et al. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. JAMA Cardiol 2020.

163. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73(24): 3168-209.

164. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circulation research 2017; 120(1): 229-43.

165. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.

166. Dashti-Khavidaki S, Khalili H. Considerations for statin therapy in patients with COVID-19. Pharmacotherapy 2020.

167. Kong F, Ye B, Lin L, et al. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-kappaB signaling in PMA-stimulated THP-1 monocytes. Biomed Pharmacother 2016; 82: 167-72.

168. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205(1): 13-9.

169. Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio 2015; 6(4): e01120.

170. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, et al. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 2014; 88(2): 913-24.

171. Violi F, Calvieri C, Ferro D, et al. Statins as antithrombotic drugs. Circulation 2013; 127(2): 251-7.

172. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360(18): 1851-61.

173. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Jama 1998; 279(20): 1643-50.

174. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020.

175. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020.

176. Grajek S, Michalak M, Gwizdala A, et al. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiologia polska 2018; 76(4): 740-9.

177. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases 2020; 20(4): 400-2.

178. Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol 2019; 71(7): 1042-55.

179. National Institutes of Health Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed 4/22/20.

180. Schunemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018; 2(22): 3198-225.

181. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384(9957): 1849-58.

182. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e195S-e226S.

183. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949-3003.

184. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332(7537): 325-9.

185. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41(4): 543-603.

186. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110(7): 874-9.

187. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341(11): 793-800.

188. Genentech’s arthritis drug tocilizumab shows promise in Covid-19 trial. April 29, 2020. Available online: <https://www.clinicaltrialsarena.com/news/french-early-trial-tocilizumab-covid-19/>. (Accessed on May 14, 2020).

189. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020.

190. Li J, Li Y, Yang B, et al. Low-molecular-weight heparin treatment for acute lung injury/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2018; 11(2): 414-22.

191. Ghezzi S, Cooper L, Rubio A, et al. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res 2017; 140: 13-7.

192. Vicenzi E, Canducci F, Pinna D, et al. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis 2004; 10(3): 413-8.

193. Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2020.

194. Smeeth L, Thomas SL, Hall AJ, et al. Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination. New England Journal of Medicine 2004; 351(25): 2611-8.

195. Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among

Hospitalized Patients with COVID-19. J Am Coll Cardiol 2020.

196. Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 2001; 7(4): 300-4.

197. Chang JC. Acute Respiratory Distress Syndrome as an Organ Phenotype of Vascular Microthrombotic Disease: Based on Hemostatic Theory and Endothelial Molecular Pathogenesis. Clin Appl Thromb Hemost 2019; 25: 1076029619887437.

198. Liu X, Li Z, Liu S, et al. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medRxiv 2020: 2020.02.27.20027557.

199. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20(4): 400-2.


200. Sarangi PP, Lee HW, Kim M. Activated protein C action in inflammation. Br J Haematol 2010; 148(6): 817-33.

201. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2012; 206(11): 1652-9.


202. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020; 382(17): e38.

203. Sun W, Li ZR, Shi ZC, et al. Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. Int Orthop 2006; 30(3): 143-6.


**Figure 1. Postulated Mechanism of Novel Treatment Options for Management of Thrombosis in COVID-19.** Panel A represents viral alveolar injury and inflammation, including fibrin deposition. Panel B shows the viral entry into the endothelial cells and the possible protective effect of hydroxychloroquine. Panel C shows the potential mechanism of effect of various agents with antithrombotic properties for mitigating thrombotic complications in COVID-19. COVID-19: coronavirus disease 2019; tPA: tissue-type plasminogen activator.



**Figure 2. Bar Graph Representing the Research Priorities as Voted by the Coauthors**



**Figure 3. Considerations for Research Investigations of Pharmacotherapy for Prevention of Thrombosis or Disease Progression in Patients with SARS-CoV-2 Infection**



\*Standard or low dose. COVID-19: coronavirus disease 2019. DAPT: dual antiplatelet therapy. DOAC: direct oral anticoagulant.

|  |  |
| --- | --- |
| **Table 1. Suggested Considerations for Prevention and Management of Thrombosis among Hospitalized Patients with COVID-19\*** | |
|  | Risk stratification for VTE should be performed for all inpatients with COVID-19. In the absence of contraindications, the vast majority of inpatients, including all patients with severe COVID-19 who are critically ill should receive prophylactic anticoagulation. |
|  | The optimal intensity of anticoagulation in patients with COVID-19 remains unknown. Although prophylactic dosing is most widely used, higher intensity of anticoagulation (including intermediate-dose and full-therapeutic anticoagulation) is being used by many clinicians/institutions. Additional studies are required to identify the optimal regimen in various patient groups with COVID-19. |
|  | For hospitalized patients with COVID-19 who require therapeutic anticoagulation (for prior indications including AF, VTE, mechanical valves; or new incident events such as new VTE or type I myocardial infarction), presence or absence of DIC, and hepatic and renal function should be considered when determining the appropriate choice of anticoagulant agent and dose.\* |
|  | Hemostatic derangements, including elevated D-dimer levels, are common among inpatients with COVID-19. The majority of a consensus panel did not find sufficient evidence for routine screening for VTE (e.g. bilateral lower extremity ultrasound, or computed tomography pulmonary angiography) for hospitalized patients with COVID-19. However, a high clinical index of suspicion for VTE should be maintained and appropriate diagnostic tests should be pursued in case of signs or symptoms for DVT (including unexplained lower extremity pain or swelling) or PE (including unexplained chest pain, unexplained right ventricular dysfunction, or hypoxemia disproportionate to the pulmonary infiltrates). |
|  | Risk stratification for VTE should be done for hospitalized patients at the time of discharge. Extended pharmacological prophylaxis (up to 45 days) should be considered for patients at high risk of VTE who do not have a high risk of bleeding. |
|  | Drug-drug interactions should be considered between investigational COVID-19 therapies and antithrombotic agents. |
| \* More detailed recommendations are provided in a separate manuscript (Bikdeli B, Madhavan MV, et al. J Am Coll Cardiol 2020).  Abbreviations: AF: atrial fibrillation, COVID-19: coronavirus disease 2019, DIC: disseminated intravascular coagulation, VTE: venous thromboembolism | |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 2. Graphical Summary of Drug-Drug Interactions between COVD-19 Investigational Therapies and Antithrombotic Agents** | | | | | | | | | |
|  | Lopinavir/Ritonavir | Remdesivir | Tocilizumab | Hydroxychloroquine | Ribavirin | Methylprednisolone | Sarilumab | Anakinra | Azithromycin |
| **FIBRINOLYTIC THERAPY** |  |  |  |  |  |  |  |  |  |
| Streptokinase |  |  |  |  |  |  |  |  |  |
| Alteplase (rtPA) | - |  |  |  |  |  |  |  |  |
| **ANTICOAGULANTS** |  |  |  |  |  |  |  |  |  |
| Unfractionated heparin |  |  |  |  |  |  |  |  |  |
| LMWH |  |  |  |  |  |  |  |  |  |
| Danaparoid | - |  |  |  |  |  |  |  |  |
| Bivalirudin | - |  |  |  |  |  |  |  |  |
| Argatroban |  |  |  |  |  |  |  |  |  |
| Fondaparinux |  |  |  |  |  |  |  |  |  |
| Vitamin-K antagonists |  |  | ψ |  | ! |  |  |  | ‡ |
| Dabigatran | \* |  |  |  |  |  |  |  | € |
| Apixaban | † |  |  |  |  |  |  |  | ¥ |
| Rivaroxaban |  |  |  |  |  |  |  |  | ¥ |
| Edoxaban |  |  |  |  |  |  |  |  |  |
| **ANTIPLATELET AGENTS** |  |  |  |  |  |  |  |  |  |
| Aspirin |  |  |  |  |  |  |  |  |  |
| Clopidogrel |  |  |  |  |  |  |  |  |  |
| Prasugrel |  |  |  |  |  |  |  |  |  |
| Ticagrelor |  |  |  |  |  |  |  |  |  |
| Cangrelor | - |  |  |  |  |  |  |  |  |
| Dipyridamole |  |  |  |  |  |  |  |  |  |
| Cilostazol | ⁋ |  |  |  |  |  |  |  |  |
| **HEMATOLOGICAL FACTORS** |  |  |  |  |  |  |  |  |  |
| Protein C | - |  |  |  |  |  |  |  |  |
| Antithrombin | - |  |  |  |  |  |  |  |  |
| Thrombomodulin | - |  | - |  |  |  | - | - |  |
|  |  |  |  |  |  |  |  |  |  |
| **\***Avoid use if CrCl < 50 ml/min. **†**50% apixaban dose reduction in patients who would otherwise receive 5 or 10 mg twice daily, and avoid in patients who would otherwise receive 2.5 mg twice daily. The Canadian product monograph states that the combination is contraindicated. **⁋**Consider reducing the cilostazol dose to 50 mg twice daily. **ψ**May decrease serum concentration of CYP3A4 substrates. Monitor INR. **!**Decreases efficacy of warfarin. **‡**May increase serum concentration, monitoring recommended. **€**P-glycoprotein inhibition: may increase serum concentration, monitoring recommended.**¥**Dose adjustments necessary when used in combination with CYP3A4 inhibitors. | | | | | | | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| Table guide | | |  |
| Low risk of interaction | Risk for mild-or moderate interaction (see legend for details) | High risk of serious interaction. Need dose adjustment or do not co-administer | No data available |

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 3. Empiric or investigational use of Agents with Antithrombotic Properties in COVID-19** | | | |
|  | **Postulated Mechanism(s) or Data from other ARDS Series** | **Clinical Evidence in Patients with COVID-19** | **Comment** |
| **ANTICOAGULANTS** |  |  |  |
| **Intermediate-dose heparin (UFH or LMWH)** | * Heparin-based products have anti-inflammatory and anti-viral properties. * Meta-analysis of 9 trials including 465 patients suggested that adjunctive LMWH was associated with significantly lower rates of mortality at 28-days in patients with ARDS (RR 0.63, 95%CI 0.41-0.96) (190). Subgroup analysis demonstrated greater effect on oxygenation in patients who received ≥5000 U/d of LMWH. * In-vitro data suggests heparin may prevent virus-induced cell death of human progenitor cells exposed to Zika virus (191). * In-vitro data suggests heparin exposure may reduce infectivity of SARS-CoV (192). | * Among a group of 449 patients admitted for COVID-19 in Wuhan, 99 (22%) received intermediate-dose UFH or LMWH (193). * No significant differences in 28-day mortality was noted in patients who received heparin-based products vs. those that did not receive heparin (30.3% vs. 297.7%, p=0.91), but anticoagulation in patients with D-dimer > 3ug/mL was associated with lower 28-day mortality (32.8% vs. 52.4%, p=0.017). | There is limited evidence, suggesting that heparin may interact with the spike S1 protein receptor domain of SARS-CoV-2 (20, 194). |
| **Therapeutic heparin (UFH or LMWH)** | * As above with intermediate-dose heparin. * Empiric heparin reduced rates of thrombotic events without increased bleeding complications in H1N1 pneumonia (25). | In a retrospective analysis, use of therapeutic anticoagulation was associated with lower mortality (adjusted HR of 0.86 per day, 95% confidence interval 0.82-0.89, p<0.001) without increased bleeding. The indication for anticoagulation, or the type of treatment were not described. Sufficient information was not provided about the co-morbidity profile of the patients (e.g., contraindications to anticoagulation).(195) | As above |
| **Danaparoid** | * Danaparoid has been shown to reduce cytokine levels and attenuate thrombosis in animal models (44, 45). * It can be administered systemically or nebulized can be given systemically. * Nebulized danaparoid can attenuate coagulation activity in the lungs and systemically as well as reduce levels of pulmonary inflammation. Animal models of lung injury suggest improved survival with its administration (46). | * No current evidence for danaparoid in COVID-19. | * Heparan sulfate moiety in danaparoid may have anti-viral actions and may restore heparan deficit on vascular endothelium. * Given minimal effect on platelets (39) and ability to be used in patients with severe renal failure (196), danaparoid may have use for thromboprophylaxis in patients with COVID-19. |
| **DOACs** | * DOACs have demonstrated mixed results with regards to inpatient and post-discharge prophylaxis for VTE (54, 57). * In patients at high risk for VTE and low risk for bleeding (including those with severe infection), betrixaban and rivaroxaban showed a net clinical benefit for inpatient thromboprophylaxis and for extended thromboprophylaxis post-hospital discharge (54, 58). | * No current evidence for DOACs in COVID-19. * There is an ongoing clinical trial assessing DOACs with DAPT, statins, and PPIs in patients with COVID-19 and suspected acute coronary syndrome (NCT04333407). | * Considerations when administering DOACs in patients with COVID-19 include longer half-life, availability of reversal agents, renal clearance, and drug-drug interactions with investigational therapies for COVID-19 (61). |
|  |  |  |  |
| **FIBRINOLYTIC AGENTS** |  |  |  |
| **Fibrinolytic therapy (including tPA)** | * There is some evidence to suggest microthrombi in the setting of ARDS and critically ill patients (197). * Urokinase and tissue-type plasminogen activator have been shown to be protective in murine models and to reduce the risk of ARDS in porcine models (77). | * Systemic fibrinolytic therapy has been used off-label in ill patients with ARDS secondary to COVID-19 with transient improvement in oxygenation and ventilatory requirement (71, 72). No long-term benefits have been established. | * Further evaluation of the role of fibrinolytics in ‘salvage’ therapy, concomitant thrombotic events (STEMI, PE, CVA)) should be explored * Further prospectively collected data in this space is needed * Established risks include major bleeding events (including intracranial hemorrhage); however, further understanding of the risk for diffuse alveolar hemorrhage is needed. |
|  |  |  |  |
| **ANTIPLATELETS** |  |  |  |
| **Aspirin** | * Aspirin is associated with diminished incidence of ARDS and improved survival in the setting of acute lung injury in animal models and observational human studies (94-99). * While prospective analyses have suggested reduced mortality when used in the pre-hospital and ICU setting.(97, 98). However, these findings were not validated in a randomized trial which evaluated its use for preventing ARDS (100). | * No current evidence for aspirin in COVID-19. * There is an ongoing clinical trial assessing DOACs with DAPT, statins, and PPIs in patients with COVID-19 and suspected acute coronary syndrome (NCT04333407). |  |
| **P2Y12 receptor antagonists** | * Ticagrelor administration within 48 hours of pneumonia diagnosis was associated with reduced circulating platelet-leukocyte aggregates, interleukin-6 levels, and improved oxygen requirements and lung function in the randomized XANTHIPPE trial (105). | * No current evidence for P2Y12 receptor inhibition in COVID-19. * There is an ongoing clinical trial assessing DOACs with DAPT, statins, and PPIs in patients with COVID-19 and suspected acute coronary syndrome (NCT04333407). | * Ticagrelor-associated dyspnea should be considered. |
| **Dipyridamole** | * The antithrombotic effect of dipyridamole is thought to be via phosphodiesterase inhibition. * Animal models suggest potential antiviral activity in the setting of influenza (113). | * A small trial randomized 22 patients to dipyridamole (150 mg PO TID) vs routine control in which the treatment group had higher hospitalization discharge rates compared to the control group (58.4% vs 20.0%), increased platelet counts, stabilization of D-dimer levels, with trends to suggest faster recovery (198). |  |
| **ANTI-INFLAMMATORY** |  |  |  |
| **Statins** | Anti-inflammatory effect: Regulation of MYD88 levels that mitigate NF-kB activation.  Anticoagulant and Antiplatelet effects: Downregulation of TF, upregulation of thrombomodulin, and inhibition of TXA2. | * No current evidence for P2Y12 receptor inhibition in COVID-19. * Several ongoing studies evaluating the use of statins in COVID-19 (NCT04348695, NCT04333407, and NCT04343001) |  |
| **Immunomodulators** | * Murine models suggest that complement inhibition may reduce severity of SARS-CoV and MERS-CoV. (36). | * Complement inhibition and JAK inhibitors have been suggested as potential therapies for COVID-19. * JAK inhibitors have been shown to have *in vitro* activity against SARS-CoV-2 (199). |  |
| **Activated protein C** | * Anti-thrombotic effect of activated protein C in early stage of sepsis-induced DIC. * Activated protein C may reduce the damage caused by ischemia/reperfusion injury, gastrointestinal inflammation, sepsis, and Ebola virus infection (130). * Anti-inflammatory and cytoprotective effects through PAR1-mediated biased signaling (200). * Recombinant activated protein C may attenuate systemic coagulopathy and pulmonary coagulopathy (133), but randomized controlled data of activated protein C for infectious or inflammatory ARDS did not improve alveolocapillary permeability nor clinical outcomes (134). | * In critically ill COVID-19 patients, 4/11 individuals had a protein C level modestly lower than the average reference values (119). | * Further study needed to determine if low levels of protein C are common and whether activated protein C or 3K3A-APC have any benefit in patients with COVID-19. |
| **Corticosteroids** | * Glucocorticoids modulate inflammatory response and coagulation factors (VWF, fibrinogen, plasminogen activator inhibitor-1) * Evidence in prior triggers for ARDS, including SARS-CoV and MERS-CoV, is conflicting (143-147). | * Retrospective analysis in COVID-19 patients with ARDS suggested reduced risk of death with methylprednisolone treatment (HR 0.38, 95% CI 0.20-0.72, p<0.001) (144). * Data from a paper currently on a pre-print server did not show any association between glucocorticoid use and 28-day mortality in critically ill patients (201). |  |
| **Hydroxychloroquine** | * Prior studies suggesting mild antiplatelet effects and possible reversal of thrombogenic properties of antiphospholipid antibodies (154, 158). * No specific studies available in ARDS. | * No current evidence for hydroxychloroquine in COVID-19. | * Data from a small case series suggests antiphospholipid data may play a role in development of thrombosis in patients with COVID-19 (202). Further data is needed to assess whether hydroxychloroquine may have a benefit in this space. |
| **OTHER** |  |  |  |
| **Antithrombin** | * Reduced levels in SARS patients who developed osteonecrosis (203). * Inflammation and coagulopathy modulation in lung injury animal models (122-124). * Increased bleeding in critically-ill trial data (126). | * When compared with 40 healthy controls, patients with COVID-19 had significantly lower antithrombin levels (121). | * Mechanisms for lower antithrombin in such patients is unclear, and this may potentially be mediated by consumption vs. reduced synthesis by the liver. |
| **Thrombomodulin** | * Anticoagulant and anti-inflammatory effects mediated through activated protein C-dependent and independent protein C mechanisms. * A systematic review suggested that recombinant thrombomodulin in patients with sepsis-induced coagulopathy was associated with reduced rates of mortality (148). | * No current evidence for thrombomodulin in COVID-19. | * Given that thrombocytopenia is not very common in COVID-19, it remains unclear if recombinant thrombomodulin would have benefit in this patient population. |
| **Contact activation system** | * Nonhuman primate models of bacterial sepsis suggest that inhibition of the contact activation system can reduce levels of inflammatory cytokines, microvascular thrombosis, and potentially contribute to improved survival (136-139). | * No current evidence for modulation of contact activation system in COVID-19. |  |
| Abbreviations: DAPT = dual antiplatelet therapy; DIC = disseminated intravascular coagulation; DOAC: direct oral anticoagulant; LMWH: low-molecular weight heparin; MERS-CoV = middle eastern respiratory syndrome coronavirus; SARS-CoV = severe acute respiratory syndrome coronavirus; UFH: unfractionated heparin | | | |

|  |  |  |
| --- | --- | --- |
| **Table 4. Research Priorities for Use of Antithrombotic Agents in Patients with COVID-19 without Diagnosed Thrombosis\*** | | |
| **Agent** | **Research priority**  **Mean (SEM)†** | **Patient subgroups of highest relevance⁋** |
| Intermediate dose Heparin (unfractionated or LMWH) | 7.82 (0.39) | Hospitalized ICU patients (62.5%)  Hospitalized ward patients (47.5%) |
| Therapeutic dose Heparin (unfractionated or LMWH) | 7.53 (0.40) | Hospitalized ICU patients (82.5%) |
| Danaparoid | 4.50 (0.40) | Hospitalized ward patients (51.3%)  Hospitalized ICU patients (35.9%) |
| Other parenteral anticoagulants (bivalirudin, argatroban, fondaparinux) | 4.89 (0.38) | Hospitalized ICU patients (56.4%)  Hospitalized ward patients (38.5%) |
| Vitamin-K antagonists | 3.08 (0.37) | Post discharge patients (50.0%)  Non-hospitalized patients (28.9%) |
| Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban) | 7.95 (0.29) | Post discharge patients (80.0%)  Non-hospitalized patients (20.0%) |
| Sulodexide | 4.50 (0.46) | Hospitalized ward patients (35.3%)  Post discharge patients (23.5%) |
| Fibrinolytic therapy | 6.20 (0.40) | Hospitalized ICU patients (86.8%) |
| Aspirin | 5.87 (0.39) | Non-hospitalized patients (46.2%)  Post discharge patients (25.6%) |
| P2Y12 receptor antagonists | 5.15 (0.40) | Non-hospitalized patients (34.2%)  Hospitalized ward patients (34.2%) |
| Dipyridamole | 4.00 (0.38) | Hospitalized ward patients (44.4%)  Non-hospitalized patients (36.1%) |
| Dual antiplatelet therapy | 4.77 (0.44) | Hospitalized ward patients (35.3%)  Post discharge patients (24.3%) |
| Antithrombin | 4.05 (0.42) | Hospitalized ICU patients (56.8%)  Hospitalized ward patients (32.4%) |
| Thrombomodulin | 4.43 (0.47) | Hospitalized ICU patients (60.6%)  Hospitalized ward patients (30.3%) |
| Activated protein C | 3.97 (0.41) | Hospitalized ICU patients (79.4%)  Hospitalized ward patients (17.6%) |
| \*Based on a survey of the Global COVID-19 Thrombosis Collaborative Group. For practical purposes, it was not possible to include all investigational agents. †From 1 to 10, ten being the highest priority. **⁋**Up to 2 categories each with >20% vote, not mutually exclusive. SEM: standard error of the mean. | | |